The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
about
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingInvolvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesiaInhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian miceA Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB ExpressionProspects of statins in Parkinson diseaseDeciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling.L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian StriatumDopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism.Statins Reduce the Risks of Relapse to Addiction in RatsDysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapyDifferential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells.Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation.Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions.Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.The protease Omi cleaves the mitogen-activated protein kinase kinase MEK1 to inhibit microglial activation.Ras-ERK Signaling in Behavior: Old Questions and New Perspectives.An experimental study on intracerebroventricular transplantation of human amniotic epithelial cells in a rat model of Parkinson's disease.Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin
P2860
Q27324174-C53D61D7-01DE-45CD-BA3B-459D2D3089E8Q28582674-A67E11EF-0764-435C-A2AD-820386FBF753Q33725654-2BD45544-4632-4E3D-A232-045E499E51D1Q33758221-B5C76845-9EAC-4EAA-8EE0-2135B2A58BD3Q34094008-7827E22A-962F-43A9-846D-56ABD6A57E2FQ34490801-A50A7A2A-7B94-42E7-A9DE-38D54390F720Q35024117-CA47798B-FE3A-4A7F-AA1B-3BC8A5CD295EQ35094028-6097DF34-2D5D-4566-95FE-B1A9E9B3B5D3Q35106605-39CB7F30-4B5F-470E-B220-A5F1E64E9738Q35424424-FA70C560-1C38-4461-8858-31D8F059D853Q36034592-71A08663-D182-4354-B580-845AF8E6DB70Q36201811-C865E0B9-8B70-4FDB-8854-13DDA16A05AEQ36799030-DA8055BB-F7C2-4E94-A18F-C0FF2712020EQ37115290-22A7A560-E800-4192-BEC6-E125D5DF9A6DQ37337494-93DD9381-09C3-4CDE-8FB2-AEA99A7DE636Q37925513-FA2E8C3F-724E-440B-AFFB-22D2C54FD274Q38207680-5DA6A438-9AEC-43F2-AD4F-00E681A3F18EQ39067400-461EDFEF-C21E-4C10-AD65-507C0E6D47CCQ39293229-21B6F8A7-B7D4-4CA6-B0A5-47E3F190C36AQ39348706-63FD9657-5753-4DAB-BB9C-472A72722513Q43059942-94FA0E0C-1B61-474E-8F7B-0EF80B431C2AQ45201060-0DCADB41-F5A4-48F4-AD8F-0AC7F40E7E4BQ45928216-297F5B41-AE40-409D-99EC-E05F86197719Q49357267-D8AE70C8-5BA0-47C5-9C19-250C146FE67AQ53573242-1FDD5CC9-D87C-4491-B889-FB4D5CD313CFQ58603118-D98BBEF3-3F39-4B33-A0A4-91A2ED5851D7
P2860
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@en
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@nl
type
label
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@en
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@nl
prefLabel
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@en
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@nl
P2093
P1476
The 3-hydroxy-3-methylglutaryl ...... erimental Parkinson's disease.
@en
P2093
Bastian Hengerer
Carina Ittrich
Jun Tang Guo
Stefan Schuster
P304
P356
10.1523/JNEUROSCI.4720-07.2008
P407
P577
2008-04-01T00:00:00Z